• How might luspatercept benefit patients with myelofibrosis?

  • Sep 12 2024
  • Duración: 8 m
  • Podcast

How might luspatercept benefit patients with myelofibrosis?

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • The MPN Hub was pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US. We asked, How might luspatercept benefit patients with myelofibrosis (MF)?

    Aaron Gerds opens by discussing the prevalence and issue of anemia in patients with MF, noting that almost all patients will become anemic at some point in the course of their disease. Gerds discusses luspatercept as a treatment option in this indication, sharing the latest clinical trial data and emphasizing the benefit of a reduction in transfusion dependency for patients treated with luspatercept. The interview closes with a look to ongoing clinical trials, including the INDEPENDENCE study and the implications of these data on future management strategies for anemic myelofibrosis.

    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre How might luspatercept benefit patients with myelofibrosis?

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles